Innovative marketing: Changes in the pharmaceutical marketing and selling; Direct to consumer (DTC) or the new P’s of marketing

Pharmaceuticals Policy and Law

Volumn 5, Issue , 2002, Pages 135-149

  Harms, F ^a   Rohmann, S ^b   Heinrich, M ^a   Druener, M ^a   Trommsdorff, V ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^b International Marketing Oncology Merck   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013598604     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. L.R. Basara, Practical considerations when evaluation DTC advertising as a marketing strategy for prescription medications, Drug Inf. J. 28 (1994), 461-470.
2. BPI: Annual Report 1999/2000.
3. BPI: Pharma innovative 1999.
4. W.G. Castagnoli, Prospects for pharmaceutical promotion, J Pharm Mark Manage 10 (1996), 223-235.
5. S.S. Cheng, Biopharmaceutical Sales and Forecasts to 2004, Spectrum (Dec. 1999), 16-1-16-16.
6. S.S. Cheng, Worldwide Sales of Health Care Products to 2002, Spectrum (Feb. 1999), 2-1-2-10.
7. P.M. DiBiaso, Providers, and Pharmaceutical Companies as Partners in the Development of Disease Management Programs, Spectrum (Nov. 1999), 4-1-4-10.
8. Direct-to-consumer advertising of prescription drugs: Withdrawal of moratorium, Federal Register 50 (1985), 36677.
9. Diversified 1998, Drug Trend Report. Edina, Minn: Diversified Pharmaceutical Services, 1998, pp. 2, 27.
10. Draft guidance for the industry: Consumer-directed broadcast advertisements: Availability, Federal Register 62 (1997), 43171.
11. F. Harms, Grosse-Wichtrup, Direct-to-Consumer (DTC) Nr. 1, PMJ 5/2000, pp. 150-154.
12. F. Harms, Grosse-Wichtrup, Direct-to-Consumer (DTC) Nr. 2, PMJ 6/2000, pp. 204-206.
13. E. Hefti, Advances in Drug Delivery Technologies, Spectrum (Oct. 1999), 10-1-10-12.
14. M. Heise and V. Lessat, European Pharmaindustry, DG-Bank, 1999.
15. R.H. Hill, Is Bigger Better? Addressing the Question of Scale in the Pharmaceutical Industry, Spectrum (May 1999), 6-1-6-12.
16. M.F. Hollon, Direct-to-Consumer; Marketing of Prescription Drugs: Creating Consumer Demand, J. of the American Med. Ass. 4 (1999), 382-384.
17. M. Hunt, Direct-to-consumer advertising of prescription drugs. Paper prepared for the National Health Policy Forum, Washington, DC, April 1998.
18. IMS Health, 1998 US pharmaceutical market. What’s on the horizon for the US pharmaceutical marketplace. Plymouth meeting 1998.
19. B.G. James, Pharmaceutical Marketing and Selling in the 21st Century, Spectrum (Nov. 1998), 16-1-16-18.
20. E.S. Jacobson, Trends in the US HMO Industry: 1998 Midjear Survey Results, Spectrum (June 1999), 3-1-3-11.
21. P.C. Langley, Integrating Pharmacoeconomics into Clinical Trials, Spectrum (June 1999), 4-1-4-10.
22. K.G. Krul, Pharmacogenomics: Key Technologies, Mayor Players, and Lingering Questions, Spectrum (Dec. 1999), 15-1-15-16.
23. V. Lee, 1998 Update: Timelines to Commercialisation for Biomedical Products, Spectrum (Dec. 1998), 18-1-18-7.
24. A. Lewis, Success Strategies for Disease Management Industry, Spectrum (April 1999), 9-1-9-8.
25. M.S. Lipsky and C.A. Taylor, The opinions and experiences of family physicians regarding directto- consumer advertising, J Fam Pract 45 (1997), 495-499.
26. P. Magyre, How Direct to Consumer Advertising Is Putting Squeeze on Physicians, ACP/ASIM Observer 1 (1999), 24-25.
27. L.A. Morris, Prescription Drug Advertising to Consumers, National Technical Information Service, 1984.
28. Navigation the Medication Marketplace: How Consumers Choose. Washington 1997: Prevention / American Pharmaceutical Association.
29. T. Nordenberg, TV drug ads that make sense, FDA Consumer Protection 32 (1998), 7-10.
30. N. Ostrove, Chief marketing Practices and Communication, FDA personal communication, 30 November 1999.
31. Pharmaceutical Research and Manufacturers of America, Industry Profile, PRMA, Washington, DC, 1998, pp. 22.
32. M. Peri and A.A. Nelson, An exploratory analysis of consumer recognition of direct-to-consumer advertising of prescription medications, J. Health Care Mark 7 (1987), 10-17.
33. Prescription drug ads to consumer audience are producing dramatic effects. Scott-Levin Associates Inc., Jan 22, 1990.
34. H.K. Shah, The Ascendance of Marketing in the New Pharmaceutical Era, Spectrum (March 1999), 3-1-3-14.
35. T.A. Shimp and R.F. Dyer, The pain pill-pleasure model and illicit drug consumption, J Consumer Res 6 (1979), 36-46.
36. R.K. Schwartz and S.B. Soumerai, Physician motivations for nonscientific prescribing, Soc Sci Med 28 (1989), 577-582.
37. E. T’Hoen, Direct-to-Consumer Advertising: For Better Profits or for Better Health? American Journal of Health-System Pharmacy 55 (1998), 594-597.
38. E. T’Hoen, Direct-to-Consumer Prescription Drug Advertising, American Journal of Law and Medicine 25 (1999), 149-169.
39. R.J. Towsend, M.D. Dibner and T.L. Wright, Demonstrating the Value of Drugs in Development: The Key Role of Pharmacoeconomics, Spectrum (Aug 1999), 6-1-6-9.
40. M.S.Wilkes, Direct-to-Consumer Prescription Drug Advertising: Trends, Impact and Implications, Health Affairs 19(2) (1998), 110-128.
41. M.S.Wilkes, Direct-to-Consumer Advertising of Prescription Drugs: An Idea Whose Time Should Not Come, British Medical Journal 318 (1999), 1301-1302.
42. VFA, Innovation - Key to Success-, 1998.